Kazuha Shosu1, Masashi Sakurai2, Kumi Inoue1, Takayuki Nakagawa3, Hiroki Sakai4, Masahiro Morimoto2, Masaru Okuda5, Shunsuke Noguchi6, Takuya Mizuno7. 1. Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yoshida, Yamaguchi, Japan. 2. Laboratory of Veterinary Pathology, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yoshida, Yamaguchi, Japan. 3. Laboratory of Veterinary Surgery, Graduate School of Agricultural and Life Sciences, University of Tokyo, Bunkyo-ku, Tokyo, Japan. 4. Laboratory of Veterinary Pathology, Department of Veterinary Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu, Japan. 5. Laboratory of Veterinary Internal Medicine, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yoshida, Yamaguchi, Japan Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yoshida, Yamaguchi, Japan. 6. Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yoshida, Yamaguchi, Japan Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yoshida, Yamaguchi, Japan. 7. Laboratory of Molecular Diagnostics and Therapeutics, Joint Faculty of Veterinary Medicine, Yamaguchi University, Yoshida, Yamaguchi, Japan Biomedical Science Center for Translational Research, The United Graduate School of Veterinary Science, Yamaguchi University, Yoshida, Yamaguchi, Japan mizutaku@yamaguchi-u.ac.jp.
Abstract
BACKGROUND: Antibody therapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) is a promising therapy in human cancer, but only limited information on PD-L1 expression in canine tumors is available. MATERIALS AND METHODS: PD-L1 expression was examined in 31 canine tumor cell lines of various origins by flow cytometry and western blotting, and in canine tumor and normal tissue specimens by immunohistochemistry. RESULTS: PD-L1 was only expressed on the cell surface of a small number of cell lines but was found expressed within the cells of almost all cell lines. Immunohistochemistry revealed that PD-L1 is frequently expressed in malignant melanoma, mammary gland tumor, mast cell tumor and lymphoma, but less frequently in soft-tissue sarcoma and hemangiosarcoma. PD-L1 was also expressed in some of the cells of normal canine tissue specimens. CONCLUSION: Canine tumors with PD-L1 expression that were identified in this study are potential candidates for antiPD-1 and antiPD-L1 therapy.
BACKGROUND: Antibody therapy targeting programmed cell death-1 (PD-1) and programmed cell death-ligand 1 (PD-L1) is a promising therapy in humancancer, but only limited information on PD-L1 expression in caninetumors is available. MATERIALS AND METHODS:PD-L1 expression was examined in 31 caninetumor cell lines of various origins by flow cytometry and western blotting, and in caninetumor and normal tissue specimens by immunohistochemistry. RESULTS:PD-L1 was only expressed on the cell surface of a small number of cell lines but was found expressed within the cells of almost all cell lines. Immunohistochemistry revealed that PD-L1 is frequently expressed in malignant melanoma, mammary gland tumor, mast cell tumor and lymphoma, but less frequently in soft-tissue sarcoma and hemangiosarcoma. PD-L1 was also expressed in some of the cells of normal canine tissue specimens. CONCLUSION:Caninetumors with PD-L1 expression that were identified in this study are potential candidates for antiPD-1 and antiPD-L1 therapy.
Authors: Deborah W Knapp; Deepika Dhawan; José A Ramos-Vara; Timothy L Ratliff; Gregory M Cresswell; Sagar Utturkar; Breann C Sommer; Christopher M Fulkerson; Noah M Hahn Journal: Front Oncol Date: 2020-01-21 Impact factor: 6.244
Authors: Belen Hernandez; Hibret A Adissu; Bih-Rong Wei; Helen T Michael; Glenn Merlino; R Mark Simpson Journal: Int J Mol Sci Date: 2018-01-30 Impact factor: 5.923
Authors: Andrew S Flies; Nicholas B Blackburn; Alan Bruce Lyons; John D Hayball; Gregory M Woods Journal: Front Immunol Date: 2017-05-03 Impact factor: 7.561